Allogene Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed September 30, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
TPG GP A, LLC filed a Schedule 13D/A amendment regarding its beneficial ownership stake in Allogene Therapeutics (market cap ~$184M). The filing is an amendment to a prior Schedule 13D but specific share counts, percentages, acquisition details, dates, and changes are not disclosed in the provided document header/metadata.
Why this rating
Amendment filing lacks substantive detail on ownership %, shares, or transaction specifics. Without concrete data, cannot assess materiality to $184M company. Routine disclosure update.
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.